• Cyclodextrin Magnetic Nano-Adsorbents for Uremic Toxins

  2026-10-01

  The reference study evaluates magnetic nanoparticles coated with α-, β-, and γ-cyclodextrin as retrievable adsorbents for uremic toxins, combining surface engineering with quantitative mass spectrometry. Its central finding is that adsorption depends strongly on surface chemistry, incubation time, and solution composition rather than simply on metabolite concentration, informing future blood-contacting adsorbent designs.

• Annexin V-FITC/7-AAD Apoptosis Kit: Decision Guide

  2026-10-01

  Learn how the Annexin V-FITC/7-AAD Apoptosis Kit converts phosphatidylserine exposure and membrane permeability into decision-ready cell death analysis. This guide connects assay interpretation with the Src/JNK-linked mitochondrial apoptosis findings reported for corynoline in osteosarcoma.

• DOT1L–Lenalidomide Synergy in Multiple Myeloma

  2026-09-30

  The reference study identifies DOT1L as a preferential epigenetic dependency in multiple myeloma and shows that its inhibition activates STING-associated innate immune signaling. These findings provide a mechanistic basis for combining DOT1L inhibition with lenalidomide to reinforce interferon responses and suppress IRF4–MYC-driven myeloma biology.

• Tetraethylammonium chloride in K+ Channel Assays

  2026-09-30

  Tetraethylammonium chloride (TEAC) provides a practical way to perturb potassium-channel conduction from either side of the pore. This guide translates that mechanism into patch-clamp, isotope-efflux, β-cell, and vascular workflows, with controls that help distinguish channel blockade from receptor or solution effects.

• Lumiracoxib in COX-2 Research Workflows

  2026-09-29

  Lumiracoxib enables selective COX-2 pathway interrogation in inflammation, ischemia, and muscle-repair models without deliberately suppressing COX-1-associated physiology. This practical guide translates time-dependent findings from a venom-induced injury study into assay design, controls, dosing pilots, and troubleshooting decisions.

• HACC-TNF-α-VLPs Enable HSP90-Dependent Cross-Presentation

  2026-09-29

  The reference study develops HACC-TNF-α-virus-like particle nanoparticles that promote HSP90-dependent antigen cross-presentation, CD8+ T-cell activation, and mucosal immunity against foot-and-mouth disease. Its combined formulation, dendritic-cell, and mouse-immunology data provide a useful framework for designing vaccine platforms that extend beyond antibody production toward cytotoxic and tissue-resident immune responses.

• Epalrestat Neuroprotection via KEAP1/Nrf2 in PD

  2026-09-28

  Jia et al. show that Epalrestat protects dopaminergic neurons in cellular and mouse Parkinson’s disease models by reducing oxidative stress and mitochondrial dysfunction. The study’s key innovation is evidence that Epalrestat directly engages KEAP1, promotes its degradation, and activates Nrf2 signaling, providing a mechanistic basis for further preclinical neuroprotection research.

• HyperScribe™ mRNA Kit for In Vivo CAR T Research

  2026-09-28

  Learn how an mRNA synthesis workflow can support research on transient CAR expression, using in vivo CD19 CAR T-cell generation in lupus mice as a practical case study. This article connects the findings to design and quality-control decisions for mRNA experiments without treating a research kit as a validated therapeutic formulation.

• Mycophenolic Acid in Whole-Blood Immunometabolism

  2026-09-27

  Use Mycophenolic acid to test how dehydrogenase inhibition reshapes stimulus-driven cytokine responses in fresh whole blood. This workflow pairs metabolic perturbation with donor-matched controls, practical compound-handling guidance, and clear limits on interpreting results beyond immunometabolism.

• TAK-242 Beyond Cytokines: Mapping TLR4 to Coagulation

  2026-09-26

  TAK-242 (Resatorvid) offers a way to probe TLR4 signaling, but translational studies should look beyond cytokines. Evidence from endotoxemic mice links TLR4 to tissue factor-positive extracellular vesicles and coagulation, while also highlighting the need to separate receptor-specific effects from parallel inflammatory pathways.

• BRCAness and Olaparib Sensitivity in Mesothelioma

  2026-09-25

  Borchert et al. investigated whether defects in homologous recombination repair, including BAP1-associated changes, could identify malignant pleural mesothelioma cells susceptible to PARP inhibition. Their in vitro results support a DNA-repair-based treatment hypothesis, while the patient-sample expression analysis provides candidate markers that require clinical validation.

• Cryo-EM Maps Full-Length αvβ3 Integrin States

  2026-09-25

  Cryo-EM analysis of full-length human αvβ3 integrin resolved six apo and five ligand-bound conformations, including previously uncharacterized intermediate states. The structures support a continuum model of integrin activation and show that CWHM-12 can stabilize distinct inhibited conformations, offering a structural basis for more precise inhibitor design.

• HyperScript™ Reverse Transcriptase in M-MuLV qPCR

  2026-09-24

  Learn when HyperScript™ Reverse Transcriptase belongs in an M-MuLV workflow—and when it does not. This assay-design guide connects RNA-to-cDNA conversion with a published qPCR strategy that distinguishes exogenous virus from endogenous retroviral sequences.

• Tigecycline Research in the Genomic Resistance Era

  2026-09-24

  Carbapenem-resistance surveillance can guide better experimental questions—but it cannot predict tigecycline susceptibility. This article connects resistance-genomics findings with a cautious, phenotype-led strategy for translational Tigecycline research.

• Annexin V-FITC/PI Apoptosis Assay Kit Guide

  2026-09-23

  Learn how to interpret Annexin V/PI staining, plan flow cytometry apoptosis detection, and troubleshoot common viability-assay questions. This scenario-driven guide explains practical use and limitations of APExBIO’s Annexin V-FITC/PI Apoptosis Assay Kit (SKU K2003).

8703 records 1/581 page Next 12345 下5页 Last page